Bausch Health Companies Inc.
NYSE:BHCDrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $3.27B
- Beta
- 0.41
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$3.19
Volume 6.83M
Average 1.70M
BHC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Bausch Health Companies Inc.NYSE: BHC
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures dips below year-ago levels
Q2 FY2026 capital expenditures of $77M (cash outflow) fell 22.2% year over year, behind the +1.8% change in trailing-twelve-month capital expenditures. Sequentially, it fell 47.6% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.
Context
- Capital expenditures amounted to 3.9% of revenue in FY2025, up 0.4 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -22.2% toward the trailing-twelve-month pace of +1.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (397M) USD
- Year-over-year change
- -17.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (397M) | -17.8% |
| FY2024 | 2024-12-31 | (337M) | -23.9% |
| FY2023 | 2023-12-31 | (272M) | -1.5% |
| FY2022 | 2022-12-31 | (268M) | +5.3% |
| FY2021 | 2021-12-31 | (283M) | — |
Capital Expenditures vs competitors
How BHC compares with its peers on the latest reported figures
- BHC's LTM Jun 2026 capital expenditures of $408.39M is the largest of the 11 companies compared; the peer median is $42.59M.
- Its year-over-year change of +1.8% is the 4th highest of 11, against a peer median of -4.0%.
- Capital expenditures amounts to 3.8% of revenue for BHC, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $408.39M | +1.8% | +14.0% | 3.8% | |
| LTM Mar 2026 | $164M | -0.6% | -4.2% | 4.5% | |
| LTM Mar 2026 | $87.3M | +15.9% | +9.6% | 15.6% | |
| LTM Jun 2026 | $76.8M | -29.9% | -1.0% | 1.9% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $69.39M | -12.0% | +21.4% | 3.0% |
| LTM Mar 2026 | $48.26M | +52.8% | +27.8% | 5.2% | |
| LTM Jun 2026 | $36.93M | -1.2% | -33.2% | 2.7% | |
| LTM Jun 2025 | $17.09M | -6.9% | -27.1% | 2.8% | |
| LTM Jun 2026 | $13.39M | +24.6% | -32.7% | 8.6% | |
| LTM Mar 2026 | $85K | -76.2% | +26.0% | 0.0% | |
| LTM Jun 2026 | $15K | -59.5% | — | — | |
| Peer median (excluding BHC) | $42.59M | -4.0% | -1.0% | 3.0% | |
Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (937M) | (212M) | (611M) | (72M) | 120M |
| Depreciation & Amortization | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B |
| Deferred Income Tax | (225M) | (176M) | 51M | 66M | 80M |
| Stock-Based Compensation | 128M | 126M | 132M | 150M | 216M |
| Change in Working Capital | (128M) | (396M) | (582M) | 7M | (222.83M) |
| Accounts Receivables | (229M) | (57M) | (195M) | (216M) | (136.35M) |
| Inventory | (16M) | (198M) | (322M) | (267M) | (12.21M) |
| Accounts Payables | 121M | (75M) | 158M | 357M | (77.33M) |
| Other Working Capital | (4M) | (66M) | (223M) | 133M | 3.05M |
| Other Non-Cash Items | 1.04B | (1.46B) | 778M | 179M | (1.17M) |
| Operating Cash Flow | 1.43B | (728M) | 1.03B | 1.6B | 1.4B |
| Capital Expenditures | (283M) | (268M) | (272M) | (337M) | (397M) |
| Acquisitions (Net) | 0 | (45M) | (1.89B) | 0 | 0 |
| Purchases of Investments | (19M) | (17M) | (27M) | (12M) | (11M) |
| Sales of Investments | 15M | 22M | 26M | 14M | 8M |
| Other Investing Activities | 682M | (45M) | (39M) | (119M) | (195M) |
| Investing Cash Flow | 409M | (303M) | (2.15B) | (454M) | (595M) |
| Debt Repayment | (1.34B) | (1.01B) | 1.58B | (799M) | (648.15M) |
| Common Stock Issued | 0 | 675M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | (26M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (173M) | (139M) | (106M) | (43M) | (93.85M) |
| Financing Cash Flow | (1.51B) | (474M) | 1.48B | (868M) | (742M) |
| Effect of Forex Changes | (19M) | (23M) | 9M | (36M) | 61M |
| Net Change in Cash | 303M | (1.53B) | 371M | 239M | 124M |
| Free Cash Flow | 1.14B | (996M) | 760M | 1.26B | 1B |
Bausch Health Companies Inc.
NYSE:BHC
Intrinsic Alpha fair value
Locked
Current Price
$8.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.